scholarly journals Identifying medications with similar packages in a Brazilian hospital: a multiple step approach

Author(s):  
Letícia L. MACIEL ◽  
Maria D. SILVA ◽  
Mariana G. NASCIMENTO ◽  
Adriano M. REIS ◽  
Renata R. MENEZES ◽  
...  

Objective: To describe the identification of drugs with similar primary packaging available in a large teaching hospital. Methods: This is a descriptive study carried out using a multi-step approach. First, the small volume parenteral drugs and oral solutions available at the institution (Step I) were listed. Then, from the list developed in Step I, groups of drugs with similar packaging (double, trio or foursome) were identified according to their characteristics (Step II). These groups were then visually evaluated by the pharmacy team (Step III), and later by the internal community of the institution (Step IV). Results: A total of 233 drugs in the pharmaceutical forms of interest were available at the institution (Stage I). In step II, 62 groups with similar primary packaging were identified. After evaluation by the pharmacy team, 19 groups remained (Stage III), which were then evaluated by the internal community, generating a final list of 15 groups of drugs with similar primary packaging. Among these, the pharmaceutical form of  parenteral use (80%) and the amber ampoule as primary packaging (46.7%) were frequent. Conclusion: The results of the study point to the applicability and adequacy of the multistep approach to identify the presence of groups of drugs with similar primary packaging in a real-world scenario. The identification of these groups of drugs in health care institutions is the first important step to plan strategies to minimize errors involving similar packaging, thus increasing the safety of medication use in the hospital environment.

2017 ◽  
Vol 2017 ◽  
pp. 1-6 ◽  
Author(s):  
Christian Napoli ◽  
Filippo Ferretti ◽  
Filippo Di Ninno ◽  
Riccardo Orioli ◽  
Alessandra Marani ◽  
...  

Health care workers (HCW) are particularly at risk of acquiring tuberculosis (TB), even in countries with low TB incidence. Therefore, TB screening in HCW is a useful prevention strategy in countries with both low and high TB incidence. Tuberculin skin test (TST) is widely used although it suffers of low specificity; on the contrary, the in vitro enzyme immunoassay tests (IGRA) show superior specificity and sensitivity but are more expensive. The present study reports the results of a three-year TB surveillance among HCW in a large teaching hospital in Rome, using TST (by standard Mantoux technique) and IGRA (by QuantiFERON-TB) as first- and second-level screening tests, respectively. Out of 2290 HCW enrolled, 141 (6.1%) had a positive TST; among them, 99 (70.2%) underwent the IGRA and 16 tested positive (16.1%). The frequency of HCW tested positive for TB seems not far from other experiences in low incidence countries. Our results confirm the higher specificity of IGRA, but, due to its higher cost, TST can be considered a good first level screening test, whose positive results should be further confirmed by IGRA before the patients undergo X-ray diagnosis and/or chemotherapy.


2005 ◽  
Vol 49 (10) ◽  
pp. 4404-4405 ◽  
Author(s):  
M. Graham ◽  
R. Nixon ◽  
L. J. Burrell ◽  
C. Bolger ◽  
P. D. R. Johnson ◽  
...  

ABSTRACT We assessed cutaneous adverse reactions (CARs) to alcohol-based hand rub (ABHR) after the introduction of a hand hygiene culture change program at our institution. CARs were infrequent among exposed health care workers (HCWs) (13/2,750; 0.47%; 1 CAR per 72 years of HCW exposure) and were not influenced by the duration or intensity of ABHR use but were associated with the presence of irritant contact dermatitis.


2019 ◽  
Vol 9 (6-s) ◽  
pp. 103-106
Author(s):  
Peddolla Sushma Reddy ◽  
Vidya Biju ◽  
Inuganti Bhavana

Background: Medication error is defined as any avertable event that may cause or lead to inappropriate medication use or patient harm while the medication is in the control of the health care professional, patient and consumer. Medication errors may occur at any stage of the medication use process including ordering, transcription, dispensing, administering and monitoring.  Objective: The objective of the study is to assess the medication errors in a tertiary care hospital and to categorize them based on their nature and type. Methodology: A prospective observational study was conducted over a period of 3 months in a tertiary care teaching hospital. This study was carried out among 240 inpatients, admitted in General Medicine department of the hospital, who were selected randomly. During the study, inpatients case records were reviewed, which includes patient’s case history, diagnosis, medication order sheets, progress chart, laboratory investigations. The data collected were analyzed for identifying medication errors such as prescribing errors and administration errors. Each reported medication error was assessed using the National Coordinating Council for Medication Error Reporting and Prevention (NCCMERP) proposed index for categorizing medication errors. Results: A total number of 240 inpatients were enrolled in the study, out of which 82 patients have developed medication errors. The overall percentage of observed medication error was 34.16%. In our study medication errors were found more in males (70.7%) than in the females (29.3%). Prescribing errors (62.19%) were the most frequently occurring type of error, which was followed by administration errors (37.8%). In our study, we found that medication errors were more with antibiotics (37) followed by NSAIDs (19). 96 prescriptions were found having drug interactions. Conclusion: This study concludes that the overall incidence of medication error was found to be 34.16%. Most of the medication errors are clinically significant and it can prevent by working together in a health care team.  


2008 ◽  
Vol 62 (7) ◽  
pp. 292 ◽  
Author(s):  
Siavash Vaziri ◽  
Farid Najafi ◽  
Farzaneh Miri ◽  
Fereshteh Jalalvandi ◽  
Afshin Almasi

2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Stewart J. Tepper ◽  
Juanzhi Fang ◽  
Pamela Vo ◽  
Ying Shen ◽  
Lujia Zhou ◽  
...  

Abstract Background Migraine is one of the leading causes of disability worldwide. Erenumab is a fully human monoclonal antibody that targets the calcitonin gene-related peptide (CGRP) receptor. This study aimed to evaluate real-world evidence on the impact of erenumab on acute medication usage and health care resource utilization (HCRU) among migraine patients. Methods This retrospective effectiveness study utilized the US Optum’s de-identified Clinformatics® Data Mart database to identify migraine patients initiating erenumab between May 1, 2018 and September 30, 2019. Patients had to be at least 18 years old, with a minimum of three doses for erenumab in the 6-month post-index period and continuous medical/pharmacy coverage in the 12-month pre- and 6-month post-index period. The date of the first claim for erenumab served as the index date. Use of acute medications overall and at different drug class level, and HCRU were compared during the 6-month pre- vs. post-index period. Impact of erenumab on a composite endpoint of three possible events: 1) outpatient visit with a diagnosis of migraine and an associated acute medication claim within 7 days of the visit, 2) hospital admission with a primary diagnosis for migraine, or 3) emergency room visit with a primary diagnosis for migraine (any events that occurred ≤3 days apart were counted only once) was also evaluated. Results The analysis included 3171 identified patients. At 6 months, following initiation of erenumab, acute medication use including the number of types of acute medication, number of claims of each medication and % of patients who received acute medication, and HCRU were significantly decreased. For the composite outcome, the mean number of events decreased from 1.03 to 0.77 (rate ratio: 0.75; 95% CI: 0.71 to 0.79; P < 0.0001). A decrease in the proportion of patients with any of the three events was also observed (52.7% vs. 39.5%, P < 0.0001). Conclusion In this retrospective analysis, erenumab was associated with significantly reduced acute medication use and HCRU in a real-world setting, hence significantly reducing the burden of the disease. A composite endpoint could be used as a proxy to evaluate the burden of migraine attacks; however, further research is needed.


Sign in / Sign up

Export Citation Format

Share Document